Online first
Original article
Published online: 2024-05-10

open access

Page views 41
Article views/downloads 39
Get Citation

Connect on Social Media

Connect on Social Media

The use of tranexamic acid in patients submitted to primary total hip and knee arthroplasty: a single-center retrospective observational study

Jaroslaw Pecold12, Maciej Krupowies12, Michal Pruc23, Marcin Tomaszewski2, Lukasz Szarpak24, Damian Swieczkowski25, Maciej Koselak6, Nicola Luigi Bragazzi7, Mahdi Al-Jeabory12

Abstract

Background: This study aimed to determine the efficacy of intravenous tranexamic acid in change in hemoglobin (Hgb) levels and need of red blood cells (RCB) transfusion following total hip arthroplasty and total knee arthroplasty when compared with non-tranexamic acid treatment. Methods: We retrospectively reviewed 33 hips and 44 knees between January 2023 and December 2023. Outcome measures were hemoglobin drop (among postoperative first day), need of red blood cells (RBC) transfusion, number of RBC units, hemoglobin levels among preoperative, and postoperative 1,2, and 5 day. Results: Among THA use of TXA compared to the non-TXA group was associated with a reduced need for RBC transfusion (12.5% vs. 32.0%; p=0.496). Drop in hemoglobin levels within the first postoperative day was significantly greater in the non-TXA group (2.4 ± 1.12) compared to the TXA group (1.48 ± 0.53; p=0.032). Among TKA patients drop in hemoglobin levels on the first postoperative day was significantly smaller in the TXA group (1.05) than in the non-TXA group (2.31), with a significant p-value of <0.001, with the need of RBC transfusion at 20% vs. 83.3%, respectively (p<0.001). Conclusion: Our study supports the use of TXA as an effective measure to reduce the need for RBC transfusion in patients undergoing THA and TKA. The findings suggest that TXA may contribute to better postoperative outcomes by maintaining higher hemoglobin levels and reducing the need for transfusion.

Article available in PDF format

View PDF Download PDF file

References

  1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159): 1789–1858.
  2. Hartley A, Gregson CL, Paternoster L, et al. Osteoarthritis: Insights Offered by the Study of Bone Mass Genetics. Curr Osteoporos Rep. 2021; 19(2): 115–122.
  3. Li L. British Columbia Osteoarthritis survey. BC: & Yukon Division, Arthritis Research Centre of Canada 2008.
  4. Lee Y, Lee SH, Lim SM, et al. Mental health and quality of life of patients with osteoarthritis pain: The sixth Korea National Health and Nutrition Examination Survey (2013-2015). PLoS One. 2020; 15(11): e0242077.
  5. Quicke JG, Conaghan PG, Corp N, et al. Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis Cartilage. 2022; 30(2): 196–206.
  6. Pecold J, Al-Jeabory M, Krupowies M, et al. Tranexamic Acid for Shoulder Arthroplasty: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 11(1): 48.
  7. Pecold J, Al-Jeabory M, Pruc M, et al. Effectiveness and safety of tranexamic acid in total knee arthroplasty: a systematic review and meta-analysis. Disaster and Emergency Medicine Journal. 2022; 7(2): 114–123.
  8. Al-Jeabory M, Gasecka A, Wieczorek W, et al. Efficacy and safety of tranexamic acid in pediatric trauma patients: Evidence from meta-analysis. Am J Emerg Med. 2021; 49: 404–405.
  9. Al-Jeabory M, Szarpak L, Attila K, et al. Efficacy and Safety of Tranexamic Acid in Emergency Trauma: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 10(5)–1030.
  10. Kimball CC, Nichols CI, Vose JG, et al. The Payer and Patient Cost Burden of Open Breast Conserving Procedures Following Percutaneous Breast Biopsy. Breast Cancer (Auckl). 2018; 4(12): 1178223418777766–3137.
  11. Zhao H, Deng YQ, Hong WX, et al. Complete genome sequence of dengue virus serotype 2 Cosmopolitan genotype strain in Guangdong, China. J Virol. 2012; 86(24): 13808–13809.
  12. Hart A, Khalil J, Carli A, et al. Blood Transfusion in Primary Total Hip and Knee Arthroplasty. Incidence, Risk Factors, and Thirty-Day Complication Rates. Journal of Bone and Joint Surgery. 2014; 96(23): 1945–1951.
  13. Blanco JF, Díaz A, Melchor FR, et al. Risk factors for periprosthetic joint infection after total knee arthroplasty. Arch Orthop Trauma Surg. 2020; 140(2): 239–245.
  14. Gylvin SH, Jørgensen CC, Fink-Jansen A, et al. Psychiatric disease as a risk factor in fast-track hip and knee replacement. Acta Orthop. 2016; 87(5): 439–443.
  15. Robinson J, Shin JI, Dowdell JE, et al. Impact of Gender on 30-Day Complications After Primary Total Joint Arthroplasty. J Arthroplasty. 2017; 32(8): 2370–2374.
  16. Suh YS, Choi HS, Lee JS, et al. Transfusion Trends of Knee Arthroplasty in Korea: A Nationwide Study Using the Korean National Health Insurance Service Sample Data. Int J Environ Res Public Health. 2022; 19(10): 5982.
  17. Picetti R, Shakur-Still H, Medcalf RL, et al. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis. 2019; 30(1): 1–10.
  18. Ahlberg A, Eriksson O, Kjellman H. Diffusion of tranexamic acid to the joint. Acta Orthop Scand. 1976; 47(5): 486–488.
  19. Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther. 2015; 47(4): 339–350.
  20. Colomina MJ, Contreras L, Guilabert P, et al. Clinical use of tranexamic acid: evidences and controversies. Braz J Anesthesiol. 2022; 72(6): 795–812.
  21. Murao S, Nakata H, Yamakawa K. Safety of tranexamic acid in thrombotic adverse events and seizure in patients with haemorrhage: a protocol for a systematic review and meta-analysis. BMJ Open. 2020; 10(6): e036020.
  22. Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015; 70 Suppl 1(1): 50-3–e18.
  23. Ipema HJ, Tanzi MG. Use of topical tranexamic acid or aminocaproic acid to prevent bleeding after major surgical procedures. Ann Pharmacother. 2012; 46(1): 97–107.
  24. Goldstein M, Feldmann C, Wulf H, et al. Tranexamic Acid Prophylaxis in Hip and Knee Joint Replacement. Dtsch Arztebl Int. 2017; 114(48): 824–830.
  25. Riaz O, Aqil A, Asmar S, et al. Epsilon-aminocaproic acid versus tranexamic acid in total knee arthroplasty: a meta-analysis study. J Orthop Traumatol. 2019; 20(1): 28.
  26. Sun Qi, Li J, Chen J, et al. Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials. BMJ Open. 2019; 9(1): e024350.
  27. Montroy J, Hutton B, Moodley P, et al. The efficacy and safety of topical tranexamic acid: A systematic review and meta-analysis. Transfus Med Rev. 2018; 19: S0887–7963.
  28. Haratian A, Shelby T, Hasan LK, et al. Utilization of Tranexamic Acid in Surgical Orthopaedic Practice: Indications and Current Considerations. Orthop Res Rev. 2021; 13: 187–199.
  29. Mitra B, Bernard SA, McArthur CJ, et al. PATCH-Trauma Investigators and the ANZICS Clinical Trials Group, PATCH-Trauma Investigators and the ANZICS Clinical Trials Group. Prehospital Tranexamic Acid for Severe Trauma. N Engl J Med. 2023; 389(2): 127–136.
  30. Ramirez RJ, Spinella PC, Bochicchio GV. Tranexamic Acid Update in Trauma. Crit Care Clin. 2017; 33(1): 85–99.